In its largest deal since 1995, Albany Molecular Research Inc. exclusively licensed a portfolio of biogenic amine reuptake inhibitors to Bristol-Myers Squibb Co. for the development of drugs to treat depression and other central nervous system disorders. (BioWorld Today)